A comparative study of low-dose quetiapine in the treatment of insomnia
Author(s): Ma Chuangsheng, Zhang Shufang, Ma Ling, Yang Jing
Pages: 131-132
Year: 2017 Issue: 2
Journal: Journal of Clinical Psychosomatic Diseases
Keyword: Insomnia; quetiapine; eszopiclone; low dose; SDRS; TESS;
Abstract: Objective To explore the efficacy and safety of low-dose quetiapine in the treatment of insomnia. Methods Fifty-six insomnia patients were assigned into study and control group of 28 ones each according to admission order,study group took orally quetiapine and the controls did eszopiclone for 4 weeks. The efficacies were assessed with the Sleep Dysfunction Rating Scale (SDRS) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS). Results Since the end of the 1st week the SDRS scores of both groups lowered more significantly compared with pretreatment (P<0.01) and group differences weren't significant in the corresponding period (P>0.05). At the end of the 4th week total effective rate was respectively 88.5% in study and 85.2% in control group,which showed no significant difference (X2=0.00,P>0.05). The incidence of adverse reactions was respectively 30.8% in study and 25.9% in control group,which showed no significant difference (X2=0.15,P>0.05). Conclusion Low-dose quetiapine has better efficacy and higher safety equivalent to eszopiclone in the treatment of insomnia.
Pages: 131-132
Year: 2017 Issue: 2
Journal: Journal of Clinical Psychosomatic Diseases
Keyword: Insomnia; quetiapine; eszopiclone; low dose; SDRS; TESS;
Abstract: Objective To explore the efficacy and safety of low-dose quetiapine in the treatment of insomnia. Methods Fifty-six insomnia patients were assigned into study and control group of 28 ones each according to admission order,study group took orally quetiapine and the controls did eszopiclone for 4 weeks. The efficacies were assessed with the Sleep Dysfunction Rating Scale (SDRS) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS). Results Since the end of the 1st week the SDRS scores of both groups lowered more significantly compared with pretreatment (P<0.01) and group differences weren't significant in the corresponding period (P>0.05). At the end of the 4th week total effective rate was respectively 88.5% in study and 85.2% in control group,which showed no significant difference (X2=0.00,P>0.05). The incidence of adverse reactions was respectively 30.8% in study and 25.9% in control group,which showed no significant difference (X2=0.15,P>0.05). Conclusion Low-dose quetiapine has better efficacy and higher safety equivalent to eszopiclone in the treatment of insomnia.
Related Articles